Virbac Stock Soars Nearly 6%, Leading the SBF 120

A 5.68% Surge Propels Virbac to the Top of the SBF 120

Virbac stock climbs 5.68% to €344.00 in mid-morning trading, up from €325.50 at the previous close. The stock now leads the SBF 120, ahead of Nanobiotix (+4.73%) and Soitec (+4.07%), while the broader index is up 0.17% at the same time. This surge follows the release of the semi-annual revenue figures on July 20, showing a 7.4% organic growth for the first half of 2026, driven by the Supercharge platforms and the integration of Thyronorm.

The performance supports the company's aim for the upper range of its 2026 forecasts, despite a 0.8% decline in North America and regulatory blockages and supply shortages in the second quarter. Today's rebound results in a 6.01% increase over the week, partially offsetting a 9.47% decline over three months. The year-on-year performance remains negative at -2.96%.

The Stock Reapproaches Its MM20 but Remains Below Medium-Term Benchmarks

Technically, today's jump brings the price back to the vicinity of the 20-session moving average at €344.98 (a -0.28% difference), after breaking the support at €329.50 in early July. The stock remains below its MM50 at €356.36 (-3.47%) and its MM200 at €349.31 (-1.52%), indicating that surpassing these benchmarks is the next step to watch. The RSI at 41 has returned to the neutral zone after a three-month period of weakness, while the MACD remains slightly negative.

The next identified resistance is at €363.50, roughly coinciding with the MM50 zone. Following the semi-annual financial release, the trajectory of North American revenues in the second half will be a key point to monitor to sustain this rebound.